4569 Stock Overview
Through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 4/6 |
Financial Health | 5/6 |
Dividends | 2/6 |
KYORIN Pharmaceutical Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥1,513.00 |
52 Week High | JP¥1,880.00 |
52 Week Low | JP¥1,499.00 |
Beta | -0.087 |
11 Month Change | -5.26% |
3 Month Change | -9.99% |
1 Year Change | -15.90% |
33 Year Change | -19.69% |
5 Year Change | -16.96% |
Change since IPO | 2.30% |
Recent News & Updates
Recent updates
Shareholder Returns
4569 | JP Pharmaceuticals | JP Market | |
---|---|---|---|
7D | -4.7% | -6.5% | -5.3% |
1Y | -15.9% | 10.6% | 7.2% |
Return vs Industry: 4569 underperformed the JP Pharmaceuticals industry which returned 10.6% over the past year.
Return vs Market: 4569 underperformed the JP Market which returned 7.2% over the past year.
Price Volatility
4569 volatility | |
---|---|
4569 Average Weekly Movement | 3.5% |
Pharmaceuticals Industry Average Movement | 4.9% |
Market Average Movement | 6.3% |
10% most volatile stocks in JP Market | 10.2% |
10% least volatile stocks in JP Market | 3.4% |
Stable Share Price: 4569 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4569's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1923 | 2,042 | Yutaka Ogihara | www.kyorin-pharm.co.jp |
KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Lyfuna for cough treatment; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex and Mometasone KYORIN, which are used as allergic rhinitis therapeutic agents; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents, intermediates, and other products.
KYORIN Pharmaceutical Co., Ltd. Fundamentals Summary
4569 fundamental statistics | |
---|---|
Market cap | JP¥88.13b |
Earnings (TTM) | JP¥5.53b |
Revenue (TTM) | JP¥120.10b |
15.7x
P/E Ratio0.7x
P/S RatioIs 4569 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4569 income statement (TTM) | |
---|---|
Revenue | JP¥120.10b |
Cost of Revenue | JP¥68.57b |
Gross Profit | JP¥51.53b |
Other Expenses | JP¥46.00b |
Earnings | JP¥5.53b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 07, 2024
Earnings per share (EPS) | 96.28 |
Gross Margin | 42.90% |
Net Profit Margin | 4.61% |
Debt/Equity Ratio | 15.9% |
How did 4569 perform over the long term?
See historical performance and comparisonDividends
3.4%
Current Dividend Yield54%
Payout RatioDoes 4569 pay a reliable dividends?
See 4569 dividend history and benchmarksKYORIN Pharmaceutical dividend dates | |
---|---|
Ex Dividend Date | Sep 27 2024 |
Dividend Pay Date | Dec 04 2024 |
Days until Ex dividend | 16 days |
Days until Dividend pay date | 84 days |
Does 4569 pay a reliable dividends?
See 4569 dividend history and benchmarks